Articles producció científica> Medicina i Cirurgia

Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality

  • Identification data

    Identifier: imarina:9267382
  • Authors:

    de Pablo-Miro, Mar
    Pujol-Ruiz, Sergi
    Iftimie, Simona
    Arenas-Miras, Maria del Mar
    Lopez-Montesinos, Inmaculada
    Duran-Jorda, Xavier
    Angles, Albert
    Grau, Santiago
    Horcajada, Juan P.
  • Others:

    Author, as appears in the article.: de Pablo-Miro, Mar; Pujol-Ruiz, Sergi; Iftimie, Simona; Arenas-Miras, Maria del Mar; Lopez-Montesinos, Inmaculada; Duran-Jorda, Xavier; Angles, Albert; Grau, Santiago; Horcajada, Juan P.;
    Department: Medicina i Cirurgia
    URV's Author/s: Iftimie Iftimie, Simona Mihaela
    Keywords: Therapy Once-weekly dalbavancin Multidrug-resistant gram-positive cocci Mortality Methicillin-resistant staphylococci Hospital stay Gram-positive Effectiveness Dalbavancin Complicated skin
    Abstract: Dalbavancin is a new antibiotic that is effective against Gram-positive microorganisms, including methicillin-resistant Staphylococci, and offers the possibility of administering intravenous therapy once weekly in an ambulatory setting. We conducted a multicenter observational case-control study, comparing all patients who received dalbavancin (cases) with hospitalized patients who were treated instead with daptomycin, linezolid or vancomycin (controls), based on clinical diagnosis, main microorganism involved, and age. The primary outcome was the length of hospital stay after starting the study antimicrobial. Secondary outcomes were 7-day and 30-day efficacy, 30-day mortality, 90-day recurrence, 90-day and 6-month hospitalization, presence of adverse events and healthcare-associated infections; 161 patients (44 cases and 117 controls) were included. Bivariate analysis showed that dalbavancin reduced the total length of hospital stay (p < 0.001), with fewer 90-day recurrences (p = 0.005), 6-month hospitalizations related to the same infection (p = 0.004) and non-related hospitalizations (p = 0.035). Multivariate analyses showed that length of hospital stay was significantly shorter in patients treated with dalbavancin (-12.05 days 95% CI [-17.00, -7.11], p < 0.001), and 30-day efficacy was higher in the dalbavancin group (OR 2.62 95% CI [1.07, 6.37], p = 0.034). Although sample size of the study may be a limitation, we can conclude that Dalbavancin is a useful antimicrobial drug against Gram-positive infections, including multidrug-resistant pathogens, and allows for a remarkable reduction in length of hospital stay with greater 30-day efficacy.
    Thematic Areas: Pharmacology, toxicology and pharmaceutics (miscellaneous) Pharmacology, toxicology and pharmaceutics (all) Pharmacology (medical) Pharmacology & pharmacy Microbiology (medical) Microbiology Infectious diseases General pharmacology, toxicology and pharmaceutics Engenharias ii Biochemistry
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: simonamihaela.iftime@urv.cat
    Author identifier: 0000-0003-0714-8414
    Record's date: 2024-07-20
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.mdpi.com/2079-6382/10/11/1296
    Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Antibiotics. 10 (11):
    APA: de Pablo-Miro, Mar; Pujol-Ruiz, Sergi; Iftimie, Simona; Arenas-Miras, Maria del Mar; Lopez-Montesinos, Inmaculada; Duran-Jorda, Xavier; Angles, Albert (2021). Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality. Antibiotics, 10(11), -. DOI: 10.3390/antibiotics10111296
    Article's DOI: 10.3390/antibiotics10111296
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2021
    Publication Type: Journal Publications
  • Keywords:

    Biochemistry,Infectious Diseases,Microbiology,Microbiology (Medical),Pharmacology & Pharmacy,Pharmacology (Medical),Pharmacology, Toxicology and Pharmaceutics (Miscellaneous)
    Therapy
    Once-weekly dalbavancin
    Multidrug-resistant gram-positive cocci
    Mortality
    Methicillin-resistant staphylococci
    Hospital stay
    Gram-positive
    Effectiveness
    Dalbavancin
    Complicated skin
    Pharmacology, toxicology and pharmaceutics (miscellaneous)
    Pharmacology, toxicology and pharmaceutics (all)
    Pharmacology (medical)
    Pharmacology & pharmacy
    Microbiology (medical)
    Microbiology
    Infectious diseases
    General pharmacology, toxicology and pharmaceutics
    Engenharias ii
    Biochemistry
  • Documents:

  • Cerca a google

    Search to google scholar